Clinical trialNCT06813911RecruitingPhase 3Interventional

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

SponsorNovartis PharmaceuticalsEnrollment340Atherosclerotic Cardiovascular Disease (ASCVD)

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

95 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Novartis Investigative Site
Yinchuan, Ningxia, China
Active, not recruiting
Novartis Investigative Site
Jining, Shandong, China
Recruiting
Novartis Investigative Site
Xian, Shanxi, China
Recruiting
Novartis Investigative Site
Beijing, China
Recruiting
Novartis Investigative Site
Shanghai, China
Recruiting

France

Novartis Investigative Site
Béziers, France
Recruiting
Novartis Investigative Site
Cholet, France
Recruiting
Novartis Investigative Site
Grenoble, France
Recruiting
Novartis Investigative Site
Lille, France
Recruiting
Novartis Investigative Site
Montpellier, France
Recruiting
Novartis Investigative Site
Paris, France
Recruiting
Novartis Investigative Site
Pessac, France
Recruiting
Novartis Investigative Site
Poitiers, France
Recruiting
Novartis Investigative Site
Toulouse, France
Recruiting

Germany

Novartis Investigative Site
Stuttgart, Baden-Wurttemberg, Germany
Recruiting
Novartis Investigative Site
Potsdam, Brandenburg, Germany
Recruiting
Novartis Investigative Site
Chemnitz, Saxony, Germany
Recruiting
Novartis Investigative Site
Leipzig, Saxony, Germany
Recruiting
Novartis Investigative Site
Berlin, Germany
Recruiting
Novartis Investigative Site
Bielefeld, Germany
Recruiting
Novartis Investigative Site
Gelnhausen, Germany
Recruiting
Novartis Investigative Site
Mannheim, Germany
Recruiting
Novartis Investigative Site
Münster, Germany
Recruiting
Novartis Investigative Site
Singen, Germany
Recruiting

Hong Kong

Novartis Investigative Site
Hong Kong, Hong Kong, Hong Kong
Recruiting
Novartis Investigative Site
Hong Kong, Hong Kong
Recruiting

Italy

Novartis Investigative Site
Ancona, AN, Italy
Recruiting
Novartis Investigative Site
Caserta, CE, Italy
Recruiting
Novartis Investigative Site
Grosseto, GR, Italy
Recruiting
Novartis Investigative Site
Milan, MI, Italy
Recruiting
Novartis Investigative Site
Rozzano, MI, Italy
Recruiting
Novartis Investigative Site
Perugia, PG, Italy
Recruiting
Novartis Investigative Site
Pordenone, PN, Italy
Recruiting
Novartis Investigative Site
Salerno, SA, Italy
Recruiting
Novartis Investigative Site
Legnago, VR, Italy
Recruiting

Netherlands

Novartis Investigative Site
The Hague, South Holland, Netherlands
Recruiting
Novartis Investigative Site
Enschede, Netherlands
Recruiting

Puerto Rico

Latin Clinical Trial Center Inc
San Juan, Puerto Rico
Alex Gonzalez Bossolo
Recruiting

Spain

Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Recruiting
Novartis Investigative Site
Pamplona, Navarre, Spain
Recruiting

55 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2025
Primary completion: 3 Feb 2028
Completion: 29 Feb 2028
Last update posted: 17 Jun 2026
Registered enrollment: 340
Registry id: NCT06813911

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.